CG Oncology to Present at Cantor Global Healthcare and Morgan Stanley Conferences.

CG Oncology, a late-stage clinical biopharmaceutical company, announced that its CEO and COO will participate in fireside chat presentations at the Cantor Global Healthcare Conference on Sept. 5 and the Morgan Stanley 23rd Annual Global Healthcare Conference on Sept. 9. Interested parties can access the live audio webcast from the company's website.

CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company, has announced that its Chairman and CEO, Arthur Kuan, and President and COO, Ambaw Bellete, will participate in fireside chat presentations at the Cantor Global Healthcare Conference on September 5 and the Morgan Stanley 23rd Annual Global Healthcare Conference on September 9. These presentations will provide investors with the opportunity to gain insights into the company's progress and future plans.

The Cantor Global Healthcare Conference is scheduled to take place on Friday, September 5, 2025, at 10:20am ET in New York, NY. The Morgan Stanley 23rd Annual Global Healthcare Conference is set for Tuesday, September 9, 2025, at 7:45am ET in New York, NY. Interested parties can access the live audio webcasts from the company's website at www.cgoncology.com. The webcast replays will be available for approximately 90 days after the live presentations.

CG Oncology is focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer. The company aims to enhance the quality of life for urologic cancer patients through innovative immunotherapies.

This announcement comes at a time when CG Oncology has been receiving significant attention from analysts and investors. The company's stock has shown mixed performance over the past year, with a drop of about 27% followed by a recent uptick of 4% over the past week and 6% over the past three months. The company's valuation metrics, such as the price-to-book ratio, have been closely watched by investors, with CG Oncology currently trading at a P/B ratio of 3.1x compared to the industry average of 2x [1].

Investors are eagerly awaiting key clinical milestones and data readouts from CG Oncology's pipeline, which could significantly impact the company's valuation and market perception. The upcoming fireside chat presentations by Arthur Kuan and Ambaw Bellete are expected to provide valuable insights into the company's progress and future prospects.

For more information on CG Oncology, please visit their website at www.cgoncology.com.

References:
[1] https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cgon/cg-oncology/news/cg-oncology-cgon-assessing-valuation-after-hc-wainwrights-bu
[2] https://finance.yahoo.com/news/cg-oncology-executive-leadership-participate-120000463.html